Johnson & Johnson, Pfizer, and Fosun Pharma Showcase Breakthrough Therapies at CIIE 2025

On November 7, at the 8th China International Import Expo 2025, multiple pharmaceutical and medical device manufacturers showcased several heavyweight new products, including many global debuts and first-time unveilings.

Johnson & Johnson: 3 Heavyweight Products"China's First Exhibition"

Johnson & Johnson's exhibition area spans medical technology and innovative pharmaceuticals, with two key products featured in the medical technology exhibits.

At this year's CIIE, Johnson & Johnson is showcasing three new products in the innovative drug sector that have yet to be approved for marketing in China, all of which are making their "China debut."IncludingThe World's First Subcutaneous Injection EGFR/MET Bispecific Antibody: Amivantamab Injection, used forNicalimab for the Treatment of Generalized Myasthenia GravisInjection, and forINLEXZO for Bladder Cancer Treatment。

NicalimabThe injectable solution is an FcRn antibody under research that Johnson & Johnson acquired through the purchase of Momenta Pharmaceuticals. It submitted a marketing application to the National Medical Products Administration in April this year and has been included in the priority review.This product is the first approved biologic product in China to undergo segmented production pilot, with the drug substance produced domestically and the formulation and packaging completed overseas.。

INLEXZOIt is regarded as a revolutionary breakthrough in the field of drug delivery for the urinary system. According to Johnson & Johnson, compared with the method of delivering gemcitabine to the bladder via catheter insertion, this product uses intravesical administration, which can achieve lasting complete remission and is expected to reduce the risk of tumor recurrence and progression. At the same time, its localized drug delivery method significantly reduces the systemic exposure of gemcitabine, greatly decreases the dosage compared with intravesical gemcitabine infusion, and due to the indwelling characteristics of the product, it can minimize the frequency of catheter insertion. In September this year, INLEXZO received approval from the U.S. FDA for marketing.

At this year's CIIE, Johnson & Johnson will unveil several innovative products in the cardiovascular field, including the "Asian debut" of the CEREGLIDE 71 Distal Access Catheter and the "China debut" of the OMNYPULS Single-Use Basket-Type Pressure Monitoring Pulsed Field Ablation Catheter.

In addition, Johnson & Johnson will showcase multiple products in the fields of eye health and orthopedics at this year's CIIE.

MSD: Highlights 30 Drugs and Vaccines Approved in China

MSD Returns to CIIE for the Seventh Consecutive Year, Showcasing Around 30 Approved Drugs and Vaccines in China under the Theme of "Innovative Science, Healthy Future"

At the vaccine exhibition area, quadrivalent and nonavalent HPV vaccines formed a "health defense line." The official exhibition board of Merck showed that the two vaccines have provided protection for more than 50 million women in China. This year, they were approved to extend to male indications, marking the first appearance of "joint prevention for both men and women" on the CIIE stage. In its anti-tumor section, as of August 2025, the immunotherapy product line has been approved for 32 indications in China, covering high-incidence cancers such as lung cancer and gastric cancer.

Rare Disease Zone Brings Back Last Year’s CIIE Debut of Targeted Drug – Leveraging the Spillover Effects of CIIE, This Drug Has Been Approved in China This Year, Saving Patients from the Hassle of Cross-border Purchases. Further Inside, the R&D Pipelines for Antivirals, Diabetes, and Cardiovascular Diseases Are Presented as a "Timeline Corridor," Allowing Visitors to View the Entire Process from Phase I Clinical Trials to Registration Submission at a Glance; Corporate Public Documents Confirm That This Corridor Will Add Over 40 New Products or Indications Within Five Years.

Pfizer: The World's First Nasal Spray for Migraine Debuts

At this year's CIIE, Pfizer is participating with the theme "For China, For the Future," showcasing a number of globally leading innovative products and solutions in the fields of oncology, anti-infectives, inflammation and immunology, migraine, rare diseases, and vaccines.

Pfizer innovatively set up the "CIIE Baby Display Zone" at its booth, showcasing 17 innovative products that have been accelerated to land in China through the CIIE platform. These products cover six major therapeutic areas: oncology, anti-infectives, inflammation and immunology, migraine, rare diseases, and vaccines.

Exhibits include the world's first and onlyThe Third Generation ALK Inhibitor Lorlatinib Tablets、An orally disintegrating tablet formulation for migraine that can achieve both acute and preventive treatment indicationsRimegepant Orally Disintegrating Tabletsetc.

As the first exhibition product this year,Zavegepant, the world's first and only nasal spray medication for the treatment of acute migraine.(Zavegepant) has attracted much attention. Zavegepant was initially developed by Bristol-Myers Squibb, then taken over by Biohaven. In May 2022, Pfizer acquired Biohaven and obtained its global rights. It was approved for marketing in the United States on March 9, 2023. It avoids the gastrointestinal adverse reactions and first-pass metabolism effects of traditional oral medications and can take effect quickly, within as fast as 15 minutes, and provide sustained headache relief for up to 48 hours. Zavegepant has not yet been officially launched in China but has been implemented in the Boao Lecheng Pilot Zone in Hainan.

At the same time, Pfizer's special exhibition area highlighted the achievements of the one-year anniversary of the "Pfizer China 2030 Strategy" announced at the 2024 CIIE. This strategy has made significant breakthroughs in accelerating innovation, improving diagnostic and treatment standards, and promoting local scientific innovation.

Fosun Pharma: DaFenqi,CAR-T、Phosphorus Absorption Inhibitors Debut

At this year's CIIE, Fosun Pharma will showcase in the Medical Devices and Healthcare Products Exhibition Area, presenting a range of globally leading innovative drugs, high-end medical devices, and international cooperation achievements. The exhibits will mainly focus on core therapeutic areas such as oncology, immune inflammation, central nervous system, and nephrology, covering comprehensive breakthroughs in medical technology innovation from diagnosis, treatment to cure.

Fosun Pharma's Key Exhibits Include:"First Exhibition" Product Revolutionary MarieVertical Particle Therapy System, China's First CAR-T Product Yikaida, Magnetic Resonance-guided Focused Ultrasound Therapy System "MagnetoWave", da Vinci Surgical Robot`, as well as the world's first and currently only approved`Phosphate Absorption Inhibitor Tenapanor Hydrochloride Tablets, and multiple products have successfully transitioned from exhibits to commercial goods. In addition, the company has accelerated its digital transformation by launching the AI-driven PharmAID decision-making platform and collaborating with various institutions to advance AI-driven drug research and development.

Rooted in China, connected globally, Fosun Pharma continues to support the realization of the "Healthy China 2030" goals through the path of "global collaboration + innovative localization."

Alcon: Three New Products Debut at "CIIE New Product Launch"

Alcon participated in the CIIE for the fourth consecutive time. At this year's CIIE, Alcon’s Surgical Products Division showcased a wide range of innovative products, including intraocular lenses (ATIOL) made from new materials to enhance comfort, as well as products supporting the treatment of glaucoma combined with cataracts.

Among them, the Clareon PanOptix Pro C+ Pro Series trifocal and trifocal toric intraocular lenses, the Clareon® AutonoMe new pneumatic preloaded product, and the Hydrus glaucoma stent made their debut at the "CIIE New Products Showcase."

Clareon PanOptix Pro C+ Pro Trifocal Intraocular Lens Series* adopts the new Clareon material and advanced manufacturing technology to achieve higher light energy utilization, providing clear visual quality and covering far, intermediate, and near vision needs. Currently, the Alcon Clareon® platform covers various types of intraocular lenses, including monofocal, multifocal, extended depth of focus, and toric lenses, meeting different vision needs, such as cataract combined with refractive errors or presbyopia patients.

At the same time, the Hydrus Microstent, introduced in the Chinese market, features a "scaffold, bypass, coverage" triple pathway innovative design, offering a solution to reduce intraocular pressure while presenting a lower risk of complications compared to traditional filtering surgery.

In addition, the Surgical Products Division has brought a series of advanced technologies and product solutions to the CIIE innovation platform, including the revolutionary [UNITY™ VCS and CS User Manual.] phacoemulsification and vitrectomy integrated surgical system Unity*, the newly approved Argos biometer, the LuxOR® Revalia surgical microscope, and the full optical personalized refractive surgery procedure.

GE：9 products are making their global debut.`, 60% led by China teams in R&D`

GE Healthcare unveiled 18 new products this time, including 9 global premieres, with 60% of them being primarily developed by the China team.

The most significant highlight is the Expert X New Quantum CT, the latest member of the Apex Quantum CT family. Equipped with 4D cardiac imaging technology, it enables precise diagnosis of structural heart disease and provides a one-stop assessment of coronary stenosis and valve function in patients with coronary artery disease combined with valvular disease. This product has not yet been launched in China.

Another heavy-hitting product from GE Healthcare is the "MR-PET" real-time metabolic MRI. This product represents the first time traditional MRI has made the leap from viewing structure to observing metabolism, and is primarily used for tumors and neurodegenerative diseases. The product was launched in China earlier this year.

Join the reader communication group:

Business Cooperation:Xiaoyu Yang 15210041717